Tight glycaemic control and cardiovascular disease in type 2 diabetes

Br J Hosp Med (Lond). 2009 Jan;70(1):31-2, 34. doi: 10.12968/hmed.2009.70.1.37692.

Abstract

The role of tight glycaemic control in reducing cardiovascular events and mortality in type 2 diabetes has not yet been firmly established. Recent clinical trials have yielded unexpected outcomes. This review summarizes the background and outcome of these trials and the implications for management of glycaemia in type 2 diabetes.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / mortality
  • Diabetic Angiopathies / mortality
  • Diabetic Angiopathies / prevention & control*
  • Glycated Hemoglobin* / drug effects
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Middle Aged
  • Risk Factors
  • Treatment Outcome

Substances

  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • hemoglobin A1c protein, human